Assembly Biosciences Inc (Nasdaq:ASMB)
April 15th, 2019
Amidst falling markets Assembly Biosciences Inc finished Monday’s trading session down 21.34%, a ($4.01) decrease to close on $14.78. As well as the drop in value, Assembly Biosciences Inc hit a new 52 week low of $13.13, breaking the previous low of $16.77 from earlier this December. Despite the drop in value, trading volumes were solid at 973.00% of normal which can indicate investor opportunities.
The market sectors were mixed Monday with a majority of the sectors trending down. Consumer Staples saw the biggest increase of the day (0.69%), while Financials saw the biggest drop (-0.62%). Information Technology has seen the biggest year-to-date gain at 23.83%.
Healthcare saw the biggest turnaround from its 5-day performance of -2.44%, as it went up 0.34%. Financials and Real Estate saw turn arounds from their five day positive performance, Financials with a drop of -0.62%.
- Consumer Staples went up with a 0.69% change.
- Healthcare went up with a 0.34% change.
- Consumer Discretionary went up with a 0.21% change.
- Communication Services went up with a 0.18% change.
- Utilities stayed even with a 0.00% change.
- Information Technology went down with a -0.04% change.
- Materials went down with a -0.46% change.
- Industrials went down with a -0.52% change.
- Energy went down with a -0.57% change.
- Real Estate went down with a -0.60% change.
- Financials went down with a -0.62% change.
Assembly Biosciences Inc Info
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company’s microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn’s disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.